Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all

J Viral Hepat. 2016 Sep;23(9):664-6. doi: 10.1111/jvh.12550. Epub 2016 Jun 8.
No abstract available

Keywords: IFN-free; PWID; drug users; hepatitis C virus; injecting; injection.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antiviral Agents
  • Hepacivirus*
  • Hepatitis C*
  • Humans
  • Substance Abuse, Intravenous

Substances

  • Antiviral Agents